首页> 外文期刊>BMC Endocrine Disorders >Insulin treatment corrects hepcidin but not YKL-40 levels in persons with type 2 diabetes mellitus matched by body mass index, waist-to-height ratio, C-reactive protein and Creatinine
【24h】

Insulin treatment corrects hepcidin but not YKL-40 levels in persons with type 2 diabetes mellitus matched by body mass index, waist-to-height ratio, C-reactive protein and Creatinine

机译:胰岛素治疗可纠正体重指数,腰围与身高比,C反应蛋白和肌酐相匹配的2型糖尿病患者中的铁调素,但不能纠正YKL-40水平

获取原文
           

摘要

Background It has been shown that hepcidin and YKL-40 levels change in persons with insulin resistance in different circumstances. However, variations of the levels of these parameters through the stages of prediabetes and type 2 diabetes mellitus are unclear. We hypothesized that hepcidin levels will decrease in persons with prediabetes, while these levels will tend to correct when persons with diabetes are treated with insulin. Finally we sought to determine the levels of YKL-40 in all groups of participants included in the study. Methods Serum hepcidin levels and YKL-40 levels were measured in control group ( n =?20), persons with prediabetes ( n =?30) and persons with diabetes on insulin therapy ( n =?30) using ELISA method. Patients in all three groups were matched by Body Mass Index, Waist-to-Height Ratio, C-Reactive Protein and creatinine levels. Results Hepcidin levels were lower in persons with prediabetes compared to control, while persons with diabetes on insulin therapy had higher values than those with prediabetes ( p =?0,00001). YKL-40 levels showed no significant changes. Conclusions Serum hepcidin levels in matched persons with prediabetes are a stronger marker of early changes in glucose metabolism compared to YKL-40 levels. Also, treatment with insulin corrects hepcidin levels, but not YKL-40 levels. Correcting levels of hepcidin is important for reducing iron-overload, which is a risk factor for diabetes.
机译:背景研究表明,在不同情况下,胰岛素抵抗患者中铁调素和YKL-40的含量会发生变化。然而,尚不清楚在糖尿病前期和2型糖尿病的各个阶段中这些参数水平的变化。我们假设前驱糖尿病患者的铁调素水平会降低,而当糖尿病患者接受胰岛素治疗时,这些水平将趋于纠正。最后,我们试图确定研究中所有参与者组中YKL-40的水平。方法采用ELISA法测定对照组(n = 20),糖尿病前期患者(n = 30)和糖尿病胰岛素治疗组(n = 30)的血清铁调素水平和YKL-40水平。三组患者均通过体重指数,腰高比,C反应蛋白和肌酐水平进行匹配。结果糖尿病前期患者中的铁调素水平低于对照组,而接受胰岛素治疗的糖尿病患者中的铁调素水平高于糖尿病前期患者(p =?00001)。 YKL-40水平无明显变化。结论与YKL-40水平相比,糖尿病前期匹配人群的血清铁调素水平是葡萄糖代谢早期变化的更强标志。同样,用胰岛素治疗可纠正铁调素水平,但不能校正YKL-40水平。纠正铁调素水平对于减少铁超载很重要,铁超载是糖尿病的危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号